- Torqur AG has signed a clinical supply agreement with Lonza for the development and manufacturing of bimiralisib, a Phase II investigational therapy.
- Lonza will provide technology transfer, process optimization, and cGMP contract manufacturing across its facilities in China and Switzerland.
Torqur AG has entered into an agreement with Lonza to support the clinical supply of bimiralisib, an investigational therapy currently in Phase II development. The collaboration will provide technology transfer, process optimization, and cGMP contract manufacturing services for the program.
Bimiralisib is a dual PI3K and mTOR inhibitor being explored across multiple indications, with its most advanced program targeting actinic keratosis, a pre-cancerous skin condition linked to chronic sun exposure. The therapy is also being developed for oncology indications, reflecting its broader therapeutic potential.
Under the agreement, Lonza will carry out manufacturing activities at its highly potent active pharmaceutical ingredient facilities in Nansha, China, and Visp, Switzerland. The CDMO will leverage its expertise in small molecule manufacturing and global infrastructure to support Torqur’s clinical-stage development program.
The collaboration is intended to provide Torqur with the manufacturing capabilities and flexibility required to advance bimiralisib toward later-stage clinical development. Lonza’s integrated services are designed to support biotech companies in progressing therapies through development and into potential commercialization.
“We are pleased to support Torqur in advancing the development of bimiralisib by leveraging our highly potent small-molecule manufacturing expertise, global facility network and cGMP manufacturing capabilities.”
Christian Seufert, Head of Advanced Synthesis at Lonza
